HMPV Treatment Market Size, Share, and Industry Analysis, By Product Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Adrenergic Agonists, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The global HMPV treatment market is witnessing significant growth, primarily driven by the increasing incidence of HMPV infections, particularly in young children and the elderly. Additionally, the increasing awareness about HMPV and other respiratory illness is expected to boost the demand for treatment.

The human metapneumovirus (HMPV) is a significant respiratory pathogen that has garnered increasing attention due to its impact on public health. Discovered in 2001, HMPV is known to cause respiratory tract infections across all the age groups, particularly affecting young children, the elderly, and individuals with weakened immune systems. The recent surge in cases reported in countries such as China and India has prompted both healthcare providers and the public to recognize HMPV's impact on the respiratory health.

• For instance, based on data published by China in December 2024, acute respiratory infections have increased and detections of seasonal influenza, rhinovirus, RSV, and HMPV, particularly in Northern provinces of China have surged.

The current treatment primarily focus on symptom management, as there is no specific antiviral treatment or vaccine available. NSAIDs and decongestants are the some of the commonly used drugs to manage the symptoms of the infection.

HMPV Treatment Market Driver

Increasing Incidence of HMPV to Boost Market Growth

The increasing incidence of human metapneumovirus (HMPV) is anticipated to significantly boost the market growth. For instance, according to an article published in the Pediatric Infectious Disease Journal in January 2024, HMPV is diagnosed in approximately 3%–10% of hospitalizations of younger children (below 5 years of age) with acute lower respiratory tract infections. This rise in hospitalizations has been particularly notable in the wake of the COVID-19 pandemic. This combination of rising incidence rates and increased awareness is poised to propel growth in the HMPV treatment market significantly.

Download Free sample to learn more about this report.

According to data published by Centers for Disease Control and Prevention (CDC) in January 2025, the total detection rate of HMPV was 1.97% in the U.S., marking a significant growth from the previous month. This demands the potential treatment for HMPV.

HMPV Treatment Market Restraint

Regulatory Hurdles Associated with Introduction of New Treatments

The regulatory hurdles associated with bringing new treatments to the market can also pose a challenge. The lengthy approval processes required for clinical trials and the need for rigorous safety evaluations can delay the introduction of potential therapies.

• For instance, in preclinical studies antiviral agents such as ribavirin and probenecid are identified to be potential candidate for the HMPV treatment. However, the transition from pre-clinical to clinical trials is often prolonged due to stringent regulatory requirements. This can slow down the new therapeutics launches in the higher demand time.

HMPV Treatment Market Opportunity

Collaborations for HMPV Treatment to Expand the Market

Collaboration in the development of treatments for human metapneumovirus (HMPV) is expected to significantly spur the market expansion. These partnerships facilitate the sharing of resources, expertise, and data, accelerating the development of effective therapies. Especially, collaborative efforts among pharmaceutical companies, research institutions for drug repurposing could offer a potential drug candidate to treat HMPV.

• For instance, ‘Antimicrobial Agents and Chemotherapy’, a study published in September 2022, highlighted promising drug repurposing efforts by identifying several existing medications that exhibit inhibitory effects against HMPV, which could accelerate the availability of effective treatments without the lengthy process of new drug discovery.

This collaborative approach is anticipated to drive the market expansion.

Segmentation

Key Insights

The report covers the following key insights:

• Incidence of HMPV, By Key Countries
• Key Industry Developments (Mergers, Acquisitions, Partnerships)
• New Product Launches, By Key Players
• Pipeline Analysis, By Key Players
• Impact of COVID-19 on the Market

Analysis by Type

Based on type, the market is divided into nonsteroidal anti-inflammatory drugs (NSAIDs), adrenergic agonists, and others.

The NSAIDs segment is expected to hold a major share of the global market. Currently, there are no approved antiviral medications specifically targeting the HMPV treatment. As no specific drugs are available, the treatment primarily focuses on symptom management, where NSAIDs play a crucial role in alleviating discomfort associated with respiratory infections. This factor is expected to fuel the segmental growth.

• For instance, American Lung Association suggest the usage of Ibuprofen and other NSAIDs.

Analysis by Route of Administration

Based on the route of administration, the market is subdivided into oral and parenteral.

The oral segment accounted for a prominent market share. This is largely due to the convenience and ease of use associated with oral medications, which are accessible for patients. Additionally, most of the management treatment for HMPV are effective in the oral form. Additionally, regulatory bodies’ recommendation is expected to fuel the segment growth.

• For instance, the World Health Organization (WHO) advises that HMPV can be managed by treating associated symptoms such as pain, fever, nasal congestion, and cough. These symptoms are typically addressed through oral medications. This trend is expected to drive the segment growth.

Analysis by Distribution Channel

Based on distribution channel, the market is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies segment holds a significant share of the market and act as the primary distribution channel for treatments. The rising incidence of HMPV outbreaks and associated hospitalizations is the key factor anticipated to drive growth in the treatment market as pharmacies provide essential clinical support to healthcare teams managing cases of HMPV.

• For instance, the article published by Max Healthcare in January 2025, new cases and hospitalization for HPMV is emerging in various countries. This enables the expansion of hospital pharmacies.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

North America accounted for a significant market share in 2024. This region holds a significant share of the HMPV treatment market due to its advanced healthcare infrastructure and high incidence rates of respiratory infections.

• As per CDC in January 2025, across Iowa, Kansas, Missouri and Nebraska, more than 5.8% of tests submitted for HMPV tested positive in the first week and which is expected to increase.

This increasing incidence and the presence of leading pharmaceutical companies and research institutions enhances the development and commercialization of HMPV therapeutics. Favorable reimbursement policies further support market growth.

Europe is the second-largest market based on the demand for HMPV treatment driven by increased awareness. The region benefits from robust healthcare systems and ongoing research initiatives aimed at developing effective treatments for respiratory infections.

The Asia Pacific region is anticipated to experience the highest CAGR during the forecast period. This growth can be largely attributed to the significant increase in HMPV transmission cases in China, which is driving up the demand for treatment.

• For instance, the Chinese Centre for Disease Control and Prevention (CDC) has reported epidemic of HMPV, across northern China since December 2024. This surge is fueling a high demand for therapeutics, propelling the regional market growth.

Key Players Covered

Due to the limitations in the current treatment options, only the symptoms are treated with the generic medications. Hence, the global HMPV treatment market is fragmented. However, there are few key players in the market.

The report includes the profiles of the following key players:

• Pfizer Inc. (U.S.)
• Dr. Reddy's Laboratories Ltd (India)
• Abbott (U.S)
• GSK Plc (U.K.)
• Sanofi (France)
• Merck & Co., Inc. (U.S.)
• Cipla (India)

Key Industry Developments

• In September 2024, Chapman University researchers secured a grant of USD 130,000 for their project “Evaluating the Impact of Human Metapneumovirus (hMPV) Infection on Infants and Children During the COVID and RSV Control Era.”
• In September 2022, the University of Texas identified an antibody that attacks a part of the human metapneumovirus, resulting in protection against the disease. This finding can result in new drug launches.